Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis

Table 1 Relationship between clinicopathological characteristics of gastric cancer patients and nuclear heat shock protein 110 expression n (%)

Factors	HSP110 expression in gastric cancer patients (n = 14)
	Low (n = 5)	High (n = 9)	P value
Age (mean ± SE)	55.2 ± 3.8	59.3 ± 2.8	0.4025
Sex,
Male	2 (22.2)	7 (77.8)	0.1575
Female	3 (60.0)	2 (40.0)
Histology
Well, Moderate	1 (33.3)	2 (66.7)	0.9227
Muc, Poor, Signet	4 (36.4)	7 (63.6)
Depth
sm, mp, ss	0 (0.0)	0 (0.0)
se, si	5 (35.7)	9 (64.3)
Lymph node metastasis
Absent	0 (0.0)	2 (100.0)	0.2549
Present	5 (41.7)	7 (58.3)
Lymphatic invasion
Absent	1 (33.3)	3 (66.7)	0.4797
Present	4 (40.0)	6 (60.0)
Venous invasion
Absent	4 (40.0)	6 (60.0)	0.5967
Present	1 (25.0)	3 (75.0)
Peritoneal lavage cytology
Negative	1 (25.0)	3 (75.0)	0.5967
Positive	4 (40.0)	6 (60.0)
Peritoneal metastasis
Absent	2 (50.0)	2 (50.0)	0.4805
Present	3 (30.0)	7 (70.0)

Well: Well-differentiated; Moderate: Moderately differentiated; Muc: Mucinous; Poor: Poorly differentiated; Signet: Signet ring cells; sm: Submucosa; mp: Muscularis propria; ss: Subserosa; se: Serosa exposed; si: Serosa infiltrating.

Table 2 Univariate analyses of clinicopathological features affecting progression-free survival rates in patients after surgery

Clinicopathological variables	Univariate analysis
	RR	95%CI	P value
Age (< 65 yr/≥ 65 yr)	2.17	0.46-8.33	0.2988
Sex (male/female)	1.62	0.48-6.22	0.4412
Histology (differentiated/undifferentiated)	2.18	0.46-8.33	0.2988
Lymph node metastasis (absent/present)	1.25	0.19-5.02	0.7822
Lymphatic invasion (absent/present)	1.29	0.33-4.29	0.6904
Venous invasion (absent/present)	1.18	0.26-4.13	0.8057
Peritoneal lavage cytology (negative/positive)	1.32	0.38-6.10	0.6766
Peritoneal metastasis (absent/present)	2.28	0.58-15.08	0.2568
HSP110 expression (low/high)	3.40	0.94-16.01	0.0625

HSP110: Heat shock protein 110.